Sputnik V registered in Kyrgyzstan

Sputnik V registered in Kyrgyzstan

Moscow, February 23, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of the Kyrgyz Republic.  

Kyrgyzstan has become the 32nd country in the world to register Sputnik V, which is now one of the world's top three coronavirus vaccines in terms of the number of approvals issued by government regulators.

Sputnik V had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino and Ghana.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Kyrgyzstan is the fourth nation in Central Asia to register Sputnik V. The vaccine will make an important contribution in promoting health safety for the people and preventing the spread of coronavirus.”

Sputnik V has a number of key advantages:

·        Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; It is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.

·        There are no strong allergies caused by Sputnik V.

·        The price of Sputnik V is less than $10 per shot, making it affordable around the world.